Severe Chronic Idiopathic Thrombocytopenic Purpura during Childhood: Definition, Management, and Prognosis

George R. Buchanan; Janna M. Journeycake; Leah Adix

doi:10.1055/s-2004-815627

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2003; 29(6): 595-604
DOI: 10.1055/s-2004-815627

Severe Chronic Idiopathic Thrombocytopenic Purpura during Childhood: Definition, Management, and Prognosis

George R. Buchanan^1,2 , Janna M. Journeycake² , Leah Adix²

¹Professor of Pediatrics, Director of Pediatric Hematology-Oncology, Division of Hematology-Oncology, Department of Pediatrics, The University of Texas Southwestern Medical Center at Dallas and The Center for Cancer and Blood Disorders, Children's Medical Center of Dallas, Dallas, Texas
²Division of Hematology-Oncology, Department of Pediatrics, The University of Texas Southwestern Medical Center at Dallas and The Center for Cancer and Blood Disorders, Children's Medical Center of Dallas, Dallas, Texas

Abstract

ABSTRACT

Chronic idiopathic thrombocytopenic purpura (ITP) can be categorized as mild, moderately severe, or severe. Severe chronic ITP during childhood is a rare disorder characterized by clinically significant mucocutaneous hemorrhage, usually in the setting of marked thrombocytopenia. It can cause substantial morbidity and rarely mortality. Many patients improve with time or even fully recover, but for those whose quality of life is negatively influenced by hemorrhage or side effects of conventional therapy (corticosteroids, intravenous immunoglobulin G, or anti-D), splenectomy is recommended. If splenectomy is unsuccessful or not feasible, other drug treatments are available, but few efficacy data exist, and the toxicity and cost of these treatments can be appreciable. Their use is best avoided outside of clinical trials conducted in specialty centers or in multi-institutional networks.

KEYWORDS

ITP - thrombocytopenia - chronic - severe - splenectomy

Full Text

References

REFERENCES

1 Kühne T, Imbach P, Bolton-Maggs P HB. et al . Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet . 2001; 358 2122-2125
2 Robb L G, Tiedeman K. Idiopathic thrombocytopenic purpura: predictors of chronic disease. Arch Dis Child . 1990; 65 502-506
3 Lowe E J, Buchanan G R. Idiopathic thrombocytopenic purpura diagnosed during the second decade of life. J Pediatr . 2003; 141 253-258
4 Reid M M. Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome. Arch Dis Child . 1995; 72 125-128
5 Blanchette V S, Carcao M D. Approach to the investigation and management of immune thrombocytopenic purpura in children. Semin Hematol . 2000; 37 299-314
6 Cines D B, Blanchette V S. Immune thrombocytopenic purpura. N Engl J Med . 2002; 346 995-1008
7 British Committee for Standards in General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol . 2003; 120 574-596
8 George J N, Woolf S H, Raskob G E. et al . Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood . 1996; 88 3-40
9 Kühne T, Imbach P. Chronic immune thrombocytopenic purpura in childhood. Semin Thromb Hemost . 1998; 24 549-553
10 Lilleyman J S. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol . 1999; 105 871-875
11 Walker R W, Walker W. Idiopathic thrombocytopenia, initial illness and long-term follow-up. Arch Dis Child . 1984; 59 316-322
12 Buchanan G R, Adix L. Outcome measures and treatment endpoints other than platelet count in childhood idiopathic thrombocytopenic purpura. Semin Thromb Hemost . 2001; 27 277-285
13 Lilleyman J S. Definitions and dogma in childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol . 1993; 10 11-14
14 Sutor A H, Grohmann A, Kaufmehl K, Wündisch T. Problems with platelet counting in thrombocytopenia. A rapid manual method to measure low platelet counts. Semin Thromb Hemost . 2001; 27 237-243
15 Wong MS-C, Chan GC-F, Ha S Y, Lau Y-L. Clinical characteristics of chronic idiopathic thrombocytopenia in Chinese children. J Pediatr Hematol Oncol . 2002; 24 648-652
16 Buchanan G R, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr . 2002; 141 683-688
17 Medeiros D, Buchanan G R. Current controversies in the management of idiopathic thrombocytopenic purpura during childhood. Pediatr Clin North Am . 1996; 43 757-772
18 Bolton-Maggs P HB, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet . 1997; 350 620-623
19 George J N. Initial management of immune thrombocytopenic purpura in children: is supportive counseling without therapeutic intervention sufficient?. J Pediatr . 2000; 137 598-600
20 Carcao M D, Blanchette V S, Stephens D. et al . Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA-100;rM). Br J Haematol . 2002; 117 961-964
21 Crosby W H. Wet purpura, dry purpura. JAMA . 1975; 232 744-745
22 Godeau B, Chevret S, Varet B, for the French AITP Study Group. et al . Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized, multicentre trial. Lancet . 2002; 359 23-29
23 Lacey J V, Penner J A. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost . 1977; 3 160-174
24 Barnard D, Woloski M, Feeny D, for the Canadian Children's Platelet Study Group. et al . Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents. J Pediatr Hematol Oncol . 2003; 25 56-62
25 Bolton-Maggs P HB, Dickerhoff R, Vora A J. The nontreatment of childhood ITP (or “the art of medicine consists of amusing the patient until nature cures the disease”). Semin Thromb Hemost . 2001; 27 269-275
26 Dickerhoff R, von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr . 2000; 137 629-632
27 Buchanan G R. ITP: how much treatment is enough?. Contemp Pediatr . 2000; 17 112-121
28 Lilleyman J S. Intracranial hemorrhage in idiopathic thrombocytopenic purpura. Arch Dis Child . 1994; 71 251-253
29 Miller E, Waight P, Farrington P. et al . Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child . 2001; 84 227-229
30 Vlacha V, Forman E N, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics . 1996; 97 738-739
31 Tarantino M D, Madden R M, Fennewald D L, Patel C C, Bertolone S J. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. J Pediatr . 1999; 134 21-26
32 Newman G C, Novoa M V, Fodero E M. et al . A dose of 75 μg/kg/d of iv anti-D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol . 2001; 112 1076-1078
33 Andrew M, Blanchette V S, Adams M. et al . A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. J Pediatr . 1992; 120 522-527
34 Bussel J B. Splenectomy-sparing strategies for the treatment and long-term maintenance of chronic idiopathic (immune) thrombocytopenic purpura. Semin Hematol . 2000; 37 1-4
35 Andersen J C. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med . 1994; 330 1560-1564
36 Kühne T, Freedman J, Semple J W. et al . Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura. J Pediatr . 1997; 130 17-24
37 Chen J-S, Wu J-M, Chen Y-J, Yeh T-F. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol . 1997; 19 526-529
38 Mantadakis E, Buchanan G R. Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol . 2000; 22 148-153
39 Szold A, Schwartz J, Abu-Abeid S, Bulvik S, Eldor A. Laparoscopic splenectomies for idiopathic thrombocytopenic purpura: experience of sixty cases. Am J Hematol . 2000; 63 7-10
40 Farah R A, Rogers Z R, Thompson W R. et al . Comparison of laparoscopic and open splenectomy in children with hematologic disorders. J Pediatr . 1997; 131 41-46
41 Holt D, Brown J, Terrill K. et al . Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura. Pediatrics . 2003; 111 87-90
42 Law C, Marcaccio M, Tam P, Heddle N, Kelton J G. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med . 1997; 336 1494-1498
43 Najean Y, Rain J-D, Billotey C. The site of destruction of autologous ¹¹¹In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol . 1997; 97 547-550
44 Hemmila M R, Foley D S, Castle V P, Hirschl R B. The response to splenectomy in pediatric patients with idiopathic thrombocytopenic purpura who fail high-dose intravenous immune globulin. J Pediatr Surg . 2000; 35 967-972
45 Williams J A, Boxer L A. Combination therapy for refractory idiopathic thrombocytopenic purpura in adolescents. J Pediatr Hematol Oncol . 2003; 25 232-235
46 Quiquandon I, Fenaux P, Caulier M T. et al . Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol . 1990; 74 223-228
47 Donato H, Kohan R, Picón A. et al . α-Interferon therapy induces improvement of platelet counts in children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol . 2001; 233 598-603
48 Hrstková H, Bajer M, Michálek, J. Recombinant human interferon α-2a therapy in children with chronic immune thrombocytopenic purpura. J Pediatr Hematol Oncol . 2002; 24 299-303
49 Stasi R, Pagano A, Stipa E L, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood . 2001; 98 952-957
50 Zecca M, Nobili B, Ramenghi U. et al . Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood . 2003; 101 3857-3861